FL 118
Alternative Names: FL-118Latest Information Update: 11 Mar 2024
At a glance
- Originator Canget BioTekpharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Colorectal cancer; Head and neck cancer; Mesothelioma; Multiple myeloma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Soft tissue sarcoma
Most Recent Events
- 08 Feb 2024 FL 118 is available for licensing as of 08 Feb 2024. http://www.canget-biotek.com/business%20models.php
- 24 Jan 2024 Preclinical trials in Colorectal cancer in USA (PO) prior to January 2024 (Canget BioTekpharma pipeline, January 2024)
- 24 Jan 2024 Preclinical trials in Head and neck cancer in USA (PO) prior to January 2024 (Canget BioTekpharma pipeline, January 2024)